Vinorelbine in Treating Children With Recurrent or Refractory Cancers

Phase 2 Completed 50 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating children with recurrent or refractory cancer.

Timeline

Start: 1998-05
Primary completion: 2006-03
Completion: 2007-03

Publications

Results Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A; Children's Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2009 Oct;53(4):590-3. doi: 10.1002/pbc.22133.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vinorelbine	Small molecule	30 mg/m2	Intravenous
Subject	Vinorelbine	Small molecule	33.75 mg/m2	Intravenous

Vinorelbine in Treating Children With Recurrent or Refractory Cancers

Summary

Timeline

Publications

Drugs

Indications